Back to search results

Hypnotherapy for Upper GI Symptoms

This study is testing if hypnotherapy sessions, delivered digitally to your own device, can help improve upper gastrointestinal (GI) symptoms. You might be able to join if you are 18 or older and experience conditions like functional dyspepsia, nausea/vomiting, or abdominal bloating. The study aims to see how much your symptoms improve using scores from questionnaires like the Irritable Bowel Symptom Severity Index (IBS-SSS) and the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) over 24 weeks. The study status is currently unclear.

Study design
This interventional study plans to enroll 100 participants. It compares digitally delivered hypnotherapy sessions to an educational module.
What's involved
You would receive seven pre-recorded hypnotherapy sessions over twelve weeks or a self-guided online educational module. You will also complete C13 breath tests and gastric alimetry testing at the start, and electronic symptom questionnaires periodically. The study lasts 24 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 weeks after the initial 12-week treatment period, for a total of 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06846359

Treatment of Upper Gastrointestinal Symptoms Using Hypnotherapy Sessions

Recruiting
NAAges 18+InterventionalTreatment
Mayo Clinic
~100 participants
Updated 2026-03-04 on ClinicalTrials.gov
What's tested:HypnotherapyEducational module

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Irritable Bowel Symptom Severity Index (IBS-SSS) score
Measured over Baseline, 12 weeks, 24 weeks
+1 more outcome measured

Conditions

GI Symptoms

Explore related trials

Abdominal DistensionDisorders of Gut-Brain InteractionNausea and VomitingNonulcer dyspepsia

NCT06846359

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Xiao Jing (Iris) Wang, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Taylor Hines
[email protected]
507-538-9959
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients will meet criteria for at least one upper GI DGBI including functional dyspepsia, any nausea/vomiting disorder, or functional abdominal bloating. Lower GI DGBIs, such as IBS, are allowable if the primary symptom is either an upper GI symptom or bloating/distension.
Participants will have had a negative 4-hour solid food gastric emptying test previously or a normal C13 Breath test at screening.
Patients with known disaccharide intolerances may be included if dietary restrictions are maintained during the duration of the study.
Patients utilizing cannabinoid based substances may be included if no dose changes are made during the duration of the study
Patients will be proficient in English language for comprehension of content
Patients will have reliable access to digital delivery systems for content and questionnaire access via smartphone over the course of the study and follow up period.
Stable doses medications are permissible, but dosing should not be changed during study period.
Patients who are pregnant.

Exclusion

Patients with known current diagnosis of small intestinal bacterial overgrowth (SIBO), gastroparesis, rumination syndrome, chronic intestinal pseudo-obstruction, advanced connective tissue diseases (e.g. scleroderma), and uncontrolled inflammatory bowel disease (IBD) will be excluded.
Patients with current untreated H. pylori infection will be excluded.
In patients with predominant bloating symptoms and constipation, those with untreated pelvic floor dysfunction will be excluded. If the predominant symptoms are nausea/vomiting or dyspepsia, or if constipation is not present, then pelvic floor dysfunction will not be exclusionary.
Patients who have a history of cognitive delay, traumatic brain injury with residual deficits, history of cerebral vascular accident with residual deficiencies in cognition, dementia, shall be excluded
Patients with significant psychiatric illness with component of psychosis (schizophrenia, bipolar disorder), as well as severe untreated major depressive disorder with suicidal ideation will be excluded
Patients with substance abuse disorders and drug addiction will be excluded.
Patients who are unlikely to comply or unlikely to benefit from psychotherapy-based interventions may be excluded at the direction of medical screening provider or principal investigator.

What this trial measures

  • Change in Irritable Bowel Symptom Severity Index (IBS-SSS) scoreBaseline, 12 weeks, 24 weeks

    The Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) is a 5-item questionnaire that rates the severity of abdominal pain, number of days with abdominal pain, distention/bloating, bowel habits, and interference in quality of life. Each question has a possible score of 100 points. The total score can range from 0 - 500, with higher scores indicating greater severity of symptoms.

  • Change in Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) scoreBaseline, 12 weeks, 24 weeks

    The Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) is a 20-item questionnaire that rates the severity of upper gastrointestinal symptoms across 6 subscales: heartburn, nausea/vomiting, fullness, bloating, upper abdominal pain, and lower abdominal pain. Subscale scores are calculated by averaging across items comprising the subscale; scores vary from 0 (none or absent) to 5 (very severe).